# Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy

> **NCT02768714** · PHASE3 · WITHDRAWN · sponsor: **Eurofarma Laboratorios S.A.**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Eurofarma's pegfilgrastim
- **DRUG:** Neulastim

## Key facts

- **NCT ID:** NCT02768714
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-01
- **Primary completion:** 2019-10
- **Final completion:** 2019-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic changes regarding the product development
- **Last updated:** 2017-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02768714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02768714, "Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02768714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*